Notes
National Health Service
Reference
NICE. NICE says pancreatic cancer drug is not cost effective for routine NHS use. Internet Document : 26 Mar 2017. Available from: URL: https://www.nice.org.uk/news/article/nice-says-pancreatic-cancer-drug-is-not-cost-effective-for-routine-nhs-use
Rights and permissions
About this article
Cite this article
NICE says etirinotecan pegol not cost effective. PharmacoEcon Outcomes News 775, 38 (2017). https://doi.org/10.1007/s40274-017-3902-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-3902-2